Cargando…

Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV

A novel injectable pre-exposure prophylaxis, cabotegravir, has greater efficacy and acceptability than oral tenofovir/emtricitabine for prevention of HIV infection. Cabotegravir is currently priced at $22 200 per year, >185 times higher than the $60–$119 estimated cost-effectiveness threshold for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pepperrell, Toby, Cross, Samuel, Hill, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830540/ https://www.ncbi.nlm.nih.gov/pubmed/36632416 http://dx.doi.org/10.1093/ofid/ofac673

Ejemplares similares

Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?
por: Sahloff, Eric G, et al.
Publicado: (2022)

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
por: Shaik, Jafar Sadik, et al.
Publicado: (2021)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection
por: Radzio-Basu, Jessica, et al.
Publicado: (2019)

Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
por: Ahluwalia, Amrit Kaur, et al.
Publicado: (2022)

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
por: Grinsztejn, Beatriz, et al.
Publicado: (2023)

Formulation and pharmacology of long-acting cabotegravir
por: Trezza, Christine, et al.
Publicado: (2015)

Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)
por: Rael, Christine Tagliaferri, et al.
Publicado: (2021)

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries
por: Jenkins, Sarah Y., et al.
Publicado: (2023)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV
por: Zondo, Nomusa M., et al.
Publicado: (2022)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa
por: Moyo, Enos, et al.
Publicado: (2022)

Pre-exposure prophylaxis of HIV
por: Naswa, Smriti, et al.
Publicado: (2011)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
por: Tolley, Elizabeth E., et al.
Publicado: (2020)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men
por: Han, Kelong, et al.
Publicado: (2022)

Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
por: Schmidt, Heather‐Marie Ann, et al.
Publicado: (2022)

HIV pre-exposure prophylaxis for women
por: Sheth, Anandi N, et al.
Publicado: (2016)

1559. Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis into Standard of Care: Baseline Results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
por: Torres, Julian A, et al.
Publicado: (2023)

1531. Early Real-World Experience of Long-Acting Cabotegravir (CAB) for HIV Pre-Exposure Prophylaxis (PrEP) in a Large Community-Based Clinic Network (CAN Community Health): Utilization and PrEP Persistence
por: Altamirano, Jessica A, et al.
Publicado: (2023)

Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2022)

The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study
por: Smith, Jennifer A, et al.
Publicado: (2020)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
por: Cutrell, Amy G., et al.
Publicado: (2021)

Pre-exposure prophylaxis for HIV: effective and underused
por: Hempel, Amanda, et al.
Publicado: (2022)

Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis
por: Jamieson, Lise, et al.
Publicado: (2022)

Pre-exposure prophylaxis in HIV
por: Khambhati, Ravi, et al.
Publicado: (2009)

HIV: Pre-exposure Prophylaxis
por: Singh, Ajai Kumar, et al.
Publicado: (2012)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
por: Pilkington, Victoria, et al.
Publicado: (2020)

Maintaining access to HIV pre-exposure prophylaxis in a pandemic: A service evaluation of telephone-based pre-exposure prophylaxis provision
por: Henderson, Lindsay, et al.
Publicado: (2022)

Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges
por: Agrahari, Vivek, et al.
Publicado: (2022)

Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2022)

Cabotegravir
Publicado: (2022)

Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
por: Davies, Olubanke, et al.
Publicado: (2016)

EquiPrEP: An implementation science protocol for promoting equitable access and uptake of long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP)
por: Kaul, Christina M., et al.
Publicado: (2023)

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
por: Pintado, Claire, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hnvh58runc59315s9budgeb7c7